Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POISE: Symptomatic Therapy vs Standard Care for Low Impact Psoriatic Oligoarthritis
NCT03797872Phase 4Completed
- Sponsor
- University of Oxford
- Start
- Apr 2019
- Primary completion
- Jul 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of methylprednisolone injection and triamcinolone in psoriatic arthritis (PsA) (2 arms), sponsored by University of Oxford. Primary endpoint: Number of Participants Who Are Eligible, Consent, and Complete the 48 Weeks Study. Started Apr 2019; status: completed.
02
Drugs
methylprednisolone injectiontriamcinolone
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT03797872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03797872.